Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 16:05 ET
|
Caribou Biosciences, Inc.
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...
Veeco Reports First Quarter 2024 Financial Results
May 07, 2024 16:05 ET
|
Veeco Instruments Inc.
First Quarter 2024 Highlights: Revenue of $174.5 million, compared with $153.5 million in the same period last yearGAAP net income of $21.9 million, or $0.37 per diluted share, compared with $8.7...
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 07, 2024 16:05 ET
|
Y-mAbs Therapeutics, Inc.
Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for...
Intapp Announces Third Quarter Fiscal Year 2024 Financial Results
May 07, 2024 16:05 ET
|
Intapp Inc.
Third quarter SaaS and support revenue of $80.8 million, up 22% year-over-yearThird quarter total revenue of $110.6 million, up 20% year-over-yearCloud annual recurring revenue (ARR) of $274.2...
Comscore Reports First Quarter 2024 Results
May 07, 2024 16:05 ET
|
Comscore, Inc.
RESTON, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media across platforms, today reported financial results for...
Open Lending Reports First Quarter 2024 Financial Results
May 07, 2024 16:05 ET
|
Open Lending Corporation
AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Open Lending Corporation (Nasdaq: LPRO) (the “Company” or “Open Lending”), an industry trailblazer in lending enablement and risk analytics solutions...
The RealReal Announces First Quarter 2024 Results
May 07, 2024 16:05 ET
|
The RealReal
Q1 2024 Gross Merchandise Value Increased 2% Year-Over-Year Q1 2024 Consignment Revenue Increased 13% Year-Over-Year Q1 2024 Net Loss Improved $51 million Year-Over-Year Q1 2024 Adjusted EBITDA Loss...
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 07, 2024 16:05 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers...
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer’s disease ongoing;...
Oculis Publishes Invitation to the Annual General Meeting
May 07, 2024 16:05 ET
|
Oculis Holding AG
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on...